Gano Kyle
Chief Executive Officer
Gano Kyle has filed 5 SEC Form 4 filings (20 transaction rows) across 1 company, with disclosures dating back to 2025. 5 of those filings fall inside the rolling window. Most recent filing: Sep 15, 2026.
On the most recent filing, Gano Kyle is listed as Chief Executive Officer at NEUROCRINE BIOSCIENCES INC. Inside the rolling window, Gano Kyle reported no open-market purchases and 2 open-market sales totaling $4.9M in NBIX. The largest disclosed transaction in the window is a sale of 36,400 NBIX shares on Jan 16, 2026, worth $4.8M.
Companies traded
Other insiders at NBIX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$4.9M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Gano Kyle made?
Gano Kyle has filed 5 SEC Form 4 filings (20 transaction rows) across 1 company since 2025.
Which companies does Gano Kyle trade?
Gano Kyle has filed SEC Form 4 disclosures for 1 company, including NBIX.
When was Gano Kyle's most recent SEC Form 4 filing?
Gano Kyle's most recent SEC Form 4 filing on Tracefour is dated Sep 15, 2026.
What is Gano Kyle's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Gano Kyle is listed as Chief Executive Officer.
What is Gano Kyle's total buy and sell value in the current window?
Inside the rolling retention window, Gano Kyle bought $0 and sold $4.9M based on SEC Form 4 filings.
What was Gano Kyle's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 36,400 NBIX shares on 2026-01-16, worth $4.8M, per SEC Form 4 filings.